Related Experiment Videos
Statin therapy in lupus-mediated atherogenesis: two birds with one stone?
Sander I van Leuven1, Yanice V Mendez-Fernandez, Erik S Stroes
1Department of Vascular Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. s.i.vanleuven@amc.uva.nl
Abstract:
The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
The JAK-STAT Signaling Pathway
Atherosclerosis I: Introduction
Peripheral Artery Disease III: Interprofessional Care